Etanercept biosimilar - Shanghai CP Guojian Pharmaceutical

Drug Profile

Etanercept biosimilar - Shanghai CP Guojian Pharmaceutical

Alternative Names: Etacept; Etanar; Reumatocept®; Yisaipu

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Developer Cipla; Shanghai CP Guojian Pharmaceutical
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Launched for Plaque psoriasis in India (SC) before March 2016
  • 17 Apr 2013 Launched for Ankylosing spondylitis in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top